Impact of Genetic Polymorphisms of Vasoactive Peptides on the Prognosis of Patients With COVID19
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- José Antônio Silva Júnior, PhD
University Ninth of July
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Guarulhos City Hall
Guarulhos, São Paulo, Brazil
- University Ninth of July
São Paulo, São Paulo, Brazil
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Jan 2022
- Primary completion
- 31 Jan 2022
- Completion
- 28 Feb 2022
- Last update posted
- 16 Dec 2021
- Registered enrollment
- 151
- Registry id
- NCT05160779
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.